欧洲 · 新闻 · Reuters
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
EyePoint on Monday said it would cut about 53% of its workforce and stop studies of its experimental eye drug for an age-related vision disease after it failed a second…
在 Reuters 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.reuters.com)
